Rehabilitation Robot Procurement Checklist: Regulatory Status, Clinical Evidence, Training, Service, and Spare Parts

Buying a rehabilitation robot is not like buying a warehouse robot. Many rehabilitation robots intended for diagnosis, treatment, or rehabilitation purposes are regulated as medical devices, but regulatory status depends on the product’s intended use and destination market. That changes everything about how you evaluate it. “FDA cleared” is not the same as “FDA approved.” CE marking under the EU MDR is not the same as CE marking under the old MDD. Clinical evidence showing improvement in one patient population does not prove superiority over conventional therapy in another. This checklist helps hospitals, rehabilitation centers, and distributors complete due diligence on regulatory status, clinical evidence, patient fit, data privacy, training, and lifecycle support before making a purchase decision. This guide is for procurement due-diligence purposes only and does not constitute medical or regulatory advice. Always consult with your regulatory affairs team and clinical staff for device-specific decisions.

Start With Intended Use and Destination Market

The first question is not “which rehabilitation robot should we buy?” It is “what do we need this device to do, and where will we use it?”

Intended use is a regulatory term. It defines the medical purpose, target patient population, clinical indications, and operating environment for which the device is legally authorized. A device cleared for gait training in stroke patients is not authorized for upper limb rehabilitation or for spinal cord injury patients unless its intended use statement explicitly covers those applications.

Using a device outside its intended use is off-label. That may carry clinical, legal, and reimbursement implications.

What to specify before evaluating any device:

The destination market determines which regulatory framework applies. A device cleared in the US under FDA 510(k) may not have CE marking under EU MDR. A device with CE under MDR may not have FDA clearance. If you operate in both markets, you need both — and the evidence packages may differ.

Regulatory Status Is Not the Same as Clinical Evidence

This is the single most important distinction in rehabilitation robot procurement. Regulatory status tells you whether a device can be legally sold. Clinical evidence tells you whether it works for a specific population. Clinical suitability tells you whether it is right for a specific patient. These are three separate questions.

Regulatory/Evidence/Document Matrix

FDA Regulatory Pathways — Terminology Must Be Precise

The FDA uses three distinct pathways for medical devices, and the terminology is not interchangeable:

“Cleared” (510(k)) is not “approved” (PMA) is not “granted” (De Novo). These terms have specific legal meanings. A device that is “FDA cleared” has been reviewed for substantial equivalence to an existing predicate device. A device that is “FDA approved” (PMA) has been independently reviewed for safety and effectiveness. The evidence requirements and review rigor are fundamentally different.

The FDA can reclassify devices from Class II to Class III if safety concerns emerge, and predicate devices can be removed from the market over time. Buyers should verify the device’s current FDA marketing status, intended use, recalls, safety communications, and any relevant reclassification actions.

What buyers must request:

• The specific 510(k) number, De Novo number, or PMA number
• The device classification (Class I, II, or III)
• The intended use statement as filed with the FDA
• Whether the device has been subject to any recalls or safety communications

CE Marking — MDR vs MDD

In the European Union, the regulatory landscape shifted significantly with the Medical Device Regulation (MDR, EU 2017/745), which replaced the older Medical Device Directive (MDD, 93/42/EEC).

MDR is a Regulation, which means it is directly binding in all EU member states. MDD was a Directive, which required each member state to transpose it into national law — leading to interpretation differences across countries. MDR eliminates that ambiguity.

MDR introduces stricter clinical evaluation requirements, enhanced traceability through UDI (Unique Device Identification) and the EUDAMED database, stronger post-market surveillance, and expanded scope (including some non-medical and aesthetic devices). Legacy devices previously certified under MDD must transition to MDR certification, with transition deadlines extending through 2027–2028 depending on risk class and conditions.

What buyers must verify:

• Which regulation the CE marking was issued under (MDD or MDR)
• The Notified Body identity (which organization issued the certificate)
• The device classification (Class I, IIa, IIb, or III)
• Whether the MDD certificate is still within its transition validity or has been recertified under MDR

A device with CE marking under MDD is still legal during the transition period, but buyers should verify the recertification timeline. A device that has already been recertified under MDR has passed more rigorous review.

How to Review Clinical Evidence Without Over-Reading It

Clinical evidence for rehabilitation robots is nuanced. Studies show improvement — but improvement is not the same as superiority, and results in one population do not transfer automatically to another.

Clinical Evidence Reading Checklist

• Identify the specific patient population in the study (stroke, SCI, TBI; acute, subacute, chronic)
• Note the sample size (typical RCT: 20–40 participants — small by medical research standards)
• Check the study design (RCT, systematic review, single-subject)
• Verify the methodological quality (PEDro score for RCTs — 5/10 or higher is acceptable)
• Identify the specific device version used in the study
• Note the outcome measures (10MWT, 6MWT, Berg Balance Scale, FMA, FAC, MAS)
• Distinguish “evidence of improvement” from “evidence of superiority”
• Check whether the study reports non-significant differences

What the evidence actually shows for gait rehabilitation robots:

A systematic review (Emam et al., 2019) of Lokomat gait training in stroke patients searched multiple databases (PubMed, Cochrane, Medline, PEDro) for RCTs with PEDro scores of 5/10 or higher. The meta-analysis showed a non-significant difference between robotic gait training and conventional therapy for cadence, 10-meter walk test, speed, and Berg balance scale. Both groups improved. The authors concluded that Lokomat “needs to be more tested.”

A separate systematic review and meta-analysis (PubMed, 2021, registered on PROSPERO CRD42020197531) examined Lokomat for balance control after stroke. Thirteen RCTs (1989–2020) were selected from seven databases. Preliminary evidence suggested Lokomat may improve balance beyond gait parameters — but “may improve” is not “proves superiority.”

For spinal cord injury, a systematic review (PubMed, 2021) of 16 studies (13 RCTs, 2 clinical trials, 1 pilot study) found evidence for beneficial effects on many motor impairments following incomplete SCI. PEDro scores ranged from 2 to 8, with a median of 6. Lokomat may improve gait speed, walking distance, and strength — but again, “may improve” is the operative phrase.

Critical reading notes:

• No study claims universal superiority of robotic gait training over conventional therapy.
• Population varies widely across studies (stroke, SCI, TBI; acute, subacute, chronic).
• Sample sizes are generally small (typical RCT: 20–40 participants).
• Device versions differ (Lokomat versions, guidance force settings, body weight support levels).
• Outcome measures vary, making cross-study comparison difficult.

Buyer consequence: Do not accept marketing claims that generalize from a single study. Ask the supplier for the specific studies supporting their claims, then check whether those studies match your patient population, your device version, and your outcome priorities.

Consider a rehabilitation center that primarily treats chronic stroke patients. A supplier presents a study showing improvement in acute stroke patients using a specific device version. The populations are different — acute patients typically show more recovery potential than chronic patients. The device version in the study may differ from the current model. If the center purchases based on that study without checking these factors, they may find that the device’s benefit in their patient population is smaller than expected — not because the device does not work, but because the evidence does not match their clinical context.

Patient Fit, Adjustment Range and Therapy Workflow

A rehabilitation robot that does not fit your patients is not a useful investment, regardless of its regulatory status or clinical evidence. Patient fit is determined by the device’s mechanical adjustment range and the therapy workflow it supports.

What to verify:

Patient fit specifications are manufacturer-specific. There is no industry-standard weight range, height range, or motor ability prerequisite. You must verify these against your actual patient population.

Therapy workflow determines how the device fits into your clinical practice. A device that requires 20 minutes of setup per patient and treats one patient at a time has a different throughput model than a device that requires 5 minutes of setup. If your facility treats 30 patients per day, setup time is a critical operational variable, not a minor detail.

Software, Data, Updates and User Accounts

Rehabilitation robots are software-dependent devices. They collect patient performance data, gait metrics, and treatment outcomes. This raises data privacy, software maintenance, and user management questions.

Data Privacy: HIPAA and GDPR

Rehabilitation robots that collect patient performance data, gait metrics, or treatment outcomes must comply with applicable regulations. The key difference: GDPR is principle-based and expansive, applying to any organization processing EU residents’ data. HIPAA is narrower and sector-specific, with gaps in certain situations (e.g., emergency contexts).

What buyers must verify:

• Where is patient data stored? (Local server, cloud, vendor-hosted?)
• Can data be exported to hospital information systems?
• Who controls user accounts and access permissions?
• Is there HIPAA or GDPR compliance documentation?
• What happens to patient data if the device is decommissioned or returned?
• Are software updates included, and for how long?

Software version control matters for clinical consistency. If a software update changes the gait training algorithm, the treatment protocol may change. Buyers should verify whether updates are mandatory, whether they can be deferred, and whether the vendor provides change logs.

Training, Onboarding and Competency Requirements

A rehabilitation robot is only as effective as the clinicians operating it. Training is not a formality — it is a safety and efficacy requirement.

What to verify:

Training content and certification requirements vary by manufacturer and jurisdiction. Some jurisdictions require specific certifications for operating medical devices. Buyers should verify local requirements, not just manufacturer recommendations.

Preventive Maintenance, Spare Parts and Service Coverage

A rehabilitation robot is a capital asset with a multi-year lifecycle (commonly estimated at 7–10 years based on industry experience, though actual service life varies by device type, usage intensity, and manufacturer support). Maintenance and service support determine whether it remains operational and clinically effective over that lifecycle.

What to verify:

Preventive maintenance schedules and spare parts supply timelines are manufacturer-specific. There is no industry standard for rehabilitation robot maintenance intervals. Buyers should request written commitments for spare parts availability — verbal assurances are not sufficient for a capital asset with a 7–10 year expected lifecycle.

Medical device surface cleaning and disinfection requirements vary by device classification and jurisdiction. FDA guidance and EU guidance may differ. Buyers should verify:

• Approved cleaning agents for the device surface
• Cleaning frequency requirements
• Whether cleaning materials are included or purchased separately
• Whether the device has any areas that require special cleaning attention (crevices, moving parts)

Documents to Request Before a Purchase Decision

Procurement Due-Diligence Checklist

Request these documents before signing a purchase agreement:

Regulatory Documents:

• FDA 510(k) clearance letter (or De Novo grant letter, or PMA approval letter)
• CE certificate with MDR or MDD basis and Notified Body identity
• Device classification (US Class I/II/III; EU Class I/IIa/IIb/III)
• Intended use statement as filed with regulatory authorities
• Any recall notices or safety communications

Clinical Evidence Documents:

• List of clinical studies cited by the manufacturer
• Full references for those studies (journal, year, DOI)
• Studies matching your patient population (not just the manufacturer’s preferred population)
• Device version used in each cited study

Patient Fit and Operational Documents:

• Patient weight and height range specifications
• Motor ability prerequisites
• Setup time and session duration specifications
• Throughput estimates (patients per day under typical conditions)

Software and Data Documents:

• HIPAA and/or GDPR compliance documentation
• Data residency and storage documentation
• Data export capabilities
• Software update policy (frequency, cost, backward compatibility)
• User account management documentation

Training Documents:

• Training curriculum and duration
• Competency assessment method
• Certification requirements (if any)
• Refresher training schedule and cost
• Maximum number of trainees per session

Service and Maintenance Documents:

• Preventive maintenance schedule
• Spare parts availability commitment (in writing, with years)
• Critical spare lead times
• Remote support capabilities
• On-site service response time guarantee
• Service contract terms and pricing
• Loaner device availability
• Approved cleaning agents and procedures

Import and Local Compliance Documents:

• Import documentation requirements for your destination country
• Local medical device registration (if required by your jurisdiction)
• Language requirements for labeling and documentation
• Any local clinical use restrictions or approvals

Key Takeaways

1. Regulatory status, clinical evidence, and clinical suitability are three separate questions. “Can it be sold?” is not “does it work?” is not “is it right for our patients?” Evaluate all three independently.
2. Terminology must be precise. “FDA cleared” (510(k)) is not “FDA approved” (PMA). CE under MDR is not CE under MDD. Request the specific regulatory numbers and verify them.
3. Clinical evidence shows improvement, not universal superiority. No study claims robotic gait training is universally superior to conventional therapy. Evidence is population-specific and device-version-specific. Match studies to your patient population.
4. Patient fit determines operational value. A device that does not fit your patients’ weight, height, or motor ability range is not useful, regardless of its regulatory status or clinical evidence.
5. Data privacy compliance is mandatory. If the device collects patient data, HIPAA (US) and/or GDPR (EU) compliance must be verified. Data residency, export capabilities, and user account management are procurement requirements.
6. Lifecycle support determines long-term value. Training, maintenance, spare parts, and software updates determine whether the device remains operational and clinically effective over its expected lifecycle. Request written commitments.